about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsVascular endothelial dysfunction and pharmacological treatmentPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile.Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studiesPCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment armsHIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.Inflammation impairs reverse cholesterol transport in vivo.Tumor-Induced Hyperlipidemia Contributes to Tumor Growth.Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.PCSK9 targets important for lipid metabolismThe Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Anti-inflammatory drugs as promising cardiovascular treatments.PCSK9 at the crossroad of cholesterol metabolism and immune function during infections.Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.Cross-talk between LOX-1 and PCSK9 in vascular tissues.Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV.Circulating PCSK9 is lowered acutely following surgery.Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.Hepatocyte nuclear factors as possible C-reactive protein transcriptional inducer in the liver and white adipose tissue of rats with experimental chronic renal failure.Praluent (Alirocumab)-Induced Renal Injury.PCSK9 inhibitors in sepsis: a new potential indication?Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery diseaseSerum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
P2860
Q26741078-5BC1FB4E-BE66-4C59-9EDD-A84ABDC1C0F3Q26774561-665895D3-01C1-42CF-80E4-FEC56C748463Q33599961-2F59AF9F-C75E-4447-82AB-47553CD40F95Q33889580-B7886F7A-1B46-4E81-A58E-F4B17DC2B66EQ33904455-A1383D53-653C-403E-A2FF-2B9C5497CEB7Q33916483-5D175564-6BB6-4FAB-966B-8869FEE9CDD3Q34122388-C7C6307C-2BFB-44F0-8C58-F6EA6A9CB118Q34433146-CF0168AC-A046-41C5-B1A3-897E08CDC96BQ34458693-6964A796-2413-4AA5-A5FA-C5E38807DE64Q34789111-E11C9E2F-1802-4BF7-AC1A-EF5A2BF21364Q35181070-C06E89C8-7E47-4222-9CE2-80D6DB40CCF0Q36727852-77D59EDF-7565-403F-AFE3-AE9C2A3084BBQ36924697-A17D7F46-AF23-4ED8-B50B-5202BF8B435BQ36956654-D0C9BF9E-9322-4980-B23C-F3598FB8191CQ36956822-8F447A13-1A05-4FED-9B0D-F54A5CC1FF0FQ37077796-2BD9031A-1852-4F78-8C81-A18DDCAB4D11Q37175221-1F73C153-BFF5-48E2-9C7E-FDE1964517D1Q37466779-A745474C-18C7-4D67-BD9A-772C6EFC8F11Q37603244-4DDAB61A-49B5-48E1-B012-CFAADC153BF7Q37703261-1968CDC1-090E-4ECA-89CD-277ADCB08A4AQ38637552-6E9E06C9-FE66-4ECB-B7C8-EF83F0E51517Q38733149-6374994A-0874-47C3-AED9-3AE09659C736Q38781922-ABE0B965-E565-4CDE-B48D-10EFF6FB0C6CQ39030028-50A0BC95-F77E-4CE5-8116-FE4838C3853CQ39051784-BB030738-FE03-413D-BE6C-98AF294F7559Q39072663-731CAE18-A58B-4D66-9E8E-ED7B63609AE1Q39237132-07C1A0C3-91FF-482D-BEDB-6F33ADDD6821Q41687081-D8DB274E-9E81-4633-ABEA-7F82AC59F642Q46712626-86FAB3CB-EA8C-490B-9B48-D731BE1F2C36Q47101735-06C0AFC9-8F8C-4252-BD17-1E8BD68F5CA6Q47143670-67CA89E2-B8D1-4F1C-B3A0-6CB735D8C1E9Q48284544-40911D49-67E4-4C50-9B79-A1BBADEDB1E8Q49269198-C6EDC115-54B0-4D53-AA7A-4F3E72F62D3DQ50057787-9692A7A0-7D87-4ADC-93F3-E1D8E6A8646DQ51187390-43E2B185-A7C1-42CF-92B8-53D6818E69D3Q51266701-461EB3A3-A401-439B-9499-57B96B8B40D9Q54971522-F592375C-BC75-41C6-B118-4768165BF7DFQ58258510-99CE46E6-68AA-4934-98F0-76E66ADAD91CQ58724610-5A791630-566D-4E83-84D2-0F802E25C683
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Inflammation stimulates the expression of PCSK9
@en
type
label
Inflammation stimulates the expression of PCSK9
@en
prefLabel
Inflammation stimulates the expression of PCSK9
@en
P2093
P2860
P1476
Inflammation stimulates the expression of PCSK9
@en
P2093
Arthur H Moser
Carl Grunfeld
Judy K Shigenaga
Kenneth R Feingold
Sophie M Patzek
P2860
P304
P356
10.1016/J.BBRC.2008.07.023
P407
P577
2008-07-16T00:00:00Z